Back to Search
Start Over
Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial
- Source :
- Revista da Sociedade Brasileira de Medicina Tropical, Volume: 55, Article number: e0191-2021, Published: 25 FEB 2022, Revista da Sociedade Brasileira de Medicina Tropical v.55 2022, Revista da Sociedade Brasileira de Medicina Tropical, Sociedade Brasileira de Medicina Tropical (SBMT), instacron:SBMT
- Publication Year :
- 2022
- Publisher :
- FapUNIFESP (SciELO), 2022.
-
Abstract
- Background:\ud Rapid molecular methods such as the line probe assay (LPA) and Xpert® MTB/RIF assay (Xpert) have been recommended by the World Health Organization for drug-resistant tuberculosis (DR-TB) diagnosis. We conducted an interventional trial in DR-TB reference centers in Brazil to evaluate the impact of the use of LPA and Xpert.\ud \ud Methods:\ud Patients with DR-TB were eligible if their drug susceptibility testing results were available to the treating physician at the time of consultation. The standard reference MGITTM 960 was compared with Xpert (arm 1) and LPA (arm 2). Effectiveness was considered as the start of the appropriate TB regimen that matched drug susceptibility testing (DST) and the proportions of culture conversion and favorable treatment outcomes after 6 months.\ud \ud Results:\ud A higher rate of empirical treatment was observed with MGIT alone than with the Xpert assay (97.0% vs. 45.0%) and LPA (98.2% vs. 67.5%). Patients started appropriate TB treatment more quickly than those in the MGIT group (median 15.0 vs. 40.5 days; p
- Subjects :
- Microbiology (medical)
Impact assessment
MDR-TB
Microbial Sensitivity Tests
Antitubercular
Sensitivity and Specificity
Vaccine Related
Rare Diseases
Antibiotics
Clinical Research
Tropical Medicine
Tuberculosis, Multidrug-Resistant
Humans
Tuberculosis
Antibiotics, Antitubercular
Diagnostics
Evaluation of treatments and therapeutic interventions
Mycobacterium tuberculosis
Multidrug-Resistant
Emerging Infectious Diseases
Orphan Drug
Good Health and Well Being
Infectious Diseases
Molecular tests
6.1 Pharmaceuticals
wf_360
HIV/AIDS
wf_220
Parasitology
Antimicrobial Resistance
wf_200
Rifampin
Infection
Brazil
Subjects
Details
- ISSN :
- 16789849 and 00378682
- Volume :
- 55
- Database :
- OpenAIRE
- Journal :
- Revista da Sociedade Brasileira de Medicina Tropical
- Accession number :
- edsair.doi.dedup.....a8bbdef01e0811fb2d47f2e902d9b6aa